Stocks · News reference
Why Is BioAge Labs Stock Sinking Friday?
BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concerns for NLRP3-targeting therapies.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target
BioAge Labs Doses First Patient In Its Phsae 2 Study Of BGE-102 To Treat Diabetic Macular Edema
BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge" or the "Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of
BioAge Labs to Present at Upcoming Investor Conferences
BioAge Labs announced the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept trial evaluating BGE-102, an oral NLRP3 inhibitor, in patients with elevated cardiovascular risk and systemic inflammation. Topline data is anticipated in the second half of 2026. The company also announced participation in three upcoming investor conferences in September 2026.
Trump's Drug Price Achievements Questioned Following Separate Most Favored Nation Contract Disclosures with Lilly, Pfizer
Public Citizen exposes separate government drug deals with Pfizer and Eli Lilly, warning the pacts could increase global drug prices.
Viking Therapeutics Announces Top-line Results From Maintenance Study Of VK2735, A Dual Agonist Of GLP-1 And Glucose-Dependent Insulinotropic Polypeptide Receptors; 22% Placebo-Adjusted Weight Loss Reported At Week 33 Following Weekly Dosing Of VK2735At 17.5 MG; No Plateau Observed
Results Demonstrate Viability of Monthly and Every Other Week Dosing Regimens for Maintaining Weight Loss; Increasing Options for Adherence to TreatmentUp to 97% of Weight Loss Maintained Following Transition to Every